Interview with Andrew D. Krahn, M.D., FHRS, head of the division of cardiology at St.
Implantable Cardioverter Defibrillator (ICD)
This channel includes news and new technology innovations for implantable cardioverter defibrillators (ICD) used to treat tachycardia arrhythmias and heart failure. This includes cardiac resynchronization therapy defibrillators (CRT-D).
-
-
May 8, 2020 — A new clinical trial is the first to compare the safety and efficacy of subcutaneous implantable cardioverter defibrillators (S-ICDs) to transvenous...
-
Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often...
-
November 6, 2019 — Cleveland Clinic announced the Top 10 Medical Innovations for 2020 at a multimedia presentation last month that capped off...
Videos | HRS | May 22, 2020
Interview with Andrew D. Krahn, M.D., FHRS, head of the division of cardiology at St. Paul’s Hospital, and professor of...
News | EP Lab | May 12, 2020
May 12, 2020 — Medtronic has received FDA approval for its Cobalt and Crome implantable cardioverter-defibrillators (...
News | Implantable Cardioverter Defibrillator (ICD) | May 08, 2020
May 8, 2020 — Final results from the UNTOUCHED study of the Emblem Subcutaneous Implantable Defibrillator (S-ICD)...
The Boston Scientific Emblem MRI-safe S-ICD system does not require a transvenous lead, leading to fewer complications with this type of ICD.
Feature | Implantable Cardioverter Defibrillator (ICD) | May 08, 2020
May 8, 2020 — A new clinical trial is the first to compare the safety and efficacy of subcutaneous implantable...
Valentina Kutyifa, M.D., Ph.D., University of Rochester Medical Center, Rochester, N.Y., is doing research in the BIO-LIBRA Study to determine it ICD or CRT-D devices work better in men or women with heart failure often present with non-ischemic cardiomyopathy.
Feature | Cardiac Resynchronization Therapy Devices (CRT) | March 09, 2020 | Valentina Kutyifa M.D., Ph.D.
Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often...
Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins.
Feature | EP Lab | November 11, 2019 | Hrishikesh Kadam
Cardiac rhythm management (CRM) devices in use today are evolving to raise the bar beyond monitoring and managing...
One of the cardiology technologies in the list of top advances in 2019 is Medtronic’s Tyrx Absorbable Antibacterial Envelope using to enclose cardiac implantable electronic devices (CIEDs). It reduced the risk of major infection by 40 percent, and pocket infection by 61 percent, based on data presented at ACC 2019.
News | November 06, 2019
November 6, 2019 — Cleveland Clinic announced the Top 10 Medical Innovations for 2020 at a multimedia presentation last...
News | Implantable Cardioverter Defibrillator (ICD) | October 11, 2019
October 11, 2019 — Medtronic plc announced the start of a worldwide pivotal study evaluating its investigational...
News | Implantable Cardioverter Defibrillator (ICD) | September 18, 2019
September 18, 2019 — Early use of an implantable cardioverter-defibrillator (ICD) after primary coronary intervention...
News | Leads Implantable Devices | August 05, 2019
August 5, 2019 — Abbott is recalling the Ellipse Implantable Cardioverter Defibrillators (ICDs) because electrical...
News | EP Lab | July 31, 2019
July 31, 2019 — The chances of patients experiencing complications after having a cardiac device implanted vary...
News | Sudden Cardiac Arrest | July 02, 2019
For patients at risk for sudden cardiac arrest (SCA) who are being evaluated for a permanent implantable cardioverter...
A physician explaining an implantable cardioverter defibrillator (ICD) to a patient. Image courtesy of Biotronik.
Feature | Implantable Cardioverter Defibrillator (ICD) | May 24, 2019 | Dave Fornell, Editor
This is a brief overview of updates on implantable cardioverter defibrillators (ICD), including new technology...
![A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.](https://www.dicardiology.com/sites/default/files/styles/content_feed_medium/public/PADIT_Infection_Risk_score.jpg?itok=Lw5DFj5l)
Figure 1: The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups, low (0-4), intermediate (5-6) and high (≥7). The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively
News | EP Lab | May 15, 2019
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The...
News | EP Lab | May 15, 2019
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices,...
